.Gamma.-Aminobutyric Acid: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for .Gamma.-Aminobutyric Acid. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Dizziness | 28% |
| Somnolence | 21.4% |
| Fatigue | 11% |
| Viral infection | 10.9% |
| Fever | 10.1% |
| Nausea and / or vomiting | 8.4% |
| Peripheral edema | 8.3% |
| Nystagmus | 8.3% |
| Hostility | 7.6% |
| Tremor | 6.8% |
| Asthenia | 5.7% |
| Diarrhea | 5.7% |
| Infection | 5.1% |
| Dry mouth | 4.8% |
| Amblyopiab | 4.2% |
| Emotional lability | 4.2% |
| Rhinitis | 4.1% |
| Constipation | 3.9% |
| Nausea | 3.9% |
| Bronchitis | 3.4% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
INDICATIONS AND USAGE Postherpetic Neuralgia Gabapentin Capsules is indicated for the management of postherpetic neuralgia in adults. Epilepsy Gabapentin Capsules is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy. Gabapentin Capsules is also indicated as adjunctive therapy in the treatment of partial seizures in pediatric patients age 3 – 12 years.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.